Validus' initial discovery started in the laboratory of Dr. Steven Dow, a renowned veterinary scientist at Colorado State University.
Unactivated mesenchymal stem cells have failed as therapeutics previously due to inability to locate to functional sites. Validus' activated MSCs migrate the to infection.
Activated mesenchymal stem cells recruit professional immune cells to the site of the infection to improve clearance.
Professional immune cells responding to infection, neutrophils, are more active engulfing bacteria when stimulated by activated mesenchymal stem cells.
Human activated mesenchymal stem cells were used to treat a chronic S. aureus infection in study mice.
Activated mesenchymal stem cells recruit more "M2 polarity" macrophage (green) compared to "M1 polarity" macrophage (red). M2 macrophage are responsible for tissue repair and rebuilding whereas M1 macrophage result in breakdown and inflammation.
Bohlson et al. and others have described the importance of appropriate immune response require to resolve a chronic infection. Frequently, the presence of a medical device or bacteria biofilm will lock the human body's immune response to infection in a persisting inflammatory state. This overly inflammatory state prevents the body's own tissue from healing appropriately. The immune response must transition to rebuilding and resolving prior to healing occurring.
Validus has found that infusing activated mesenchymal cells into animals with chronic infections helps shift the immune response from primarily inflammatory to primarily resolving.